OpiCalc Logo

OpiCalc

--- Clinical Tools

Logo
OpiCalc
ASCVD RiskBMI & Ideal WeightCentor CriteriaFramingham RiskGAD-7Opioid ConversionPHQ-9Preventive Screening

Clinical Evidence and Methodology

EVIDENCE SYNTHESIS

Clinical Reference Hub

Curated insights • How it Works • Practical Pearls • Evidence Base

CLINICAL INSIGHT

When to Use

When to Use

  • Primary prevention risk assessment for cardiovascular disease (CVD).
  • Estimating the 10-year risk of developing coronary heart disease (CHD) events (MI and coronary death).
  • Decision support for blood pressure management and lifestyle interventions.

Target Population

Historically validated in primarily White populations. Best used for adults aged 30–74 years without established CVD or diabetes.

CLINICAL INSIGHT

How it Works

Assessed Variables

  • Age
  • Total Cholesterol
  • HDL Cholesterol
  • Systolic Blood Pressure (and treatment status)
  • Smoking Status

Risk Categories

< 10%
10–20%
> 20%
CLINICAL INSIGHT

Practical Pearls

Legacy vs. Modern Tools

The Framingham Risk Score was the gold standard for decades. However, modern guidelines (AHA/ACC) now prefer the Pooled Cohort Equations (ASCVD Risk) as they include stroke as an endpoint and are better calibrated for diverse populations.

CLINICAL INSIGHT

Next Steps

Complementary Calculators

CLINICAL INSIGHT

Evidence Base

Primary Derivation

Prediction of coronary heart disease using risk factor categories.

Wilson PW, et al.Circulation.1998

Framingham Risk

Framingham 10-Year CVD Risk: Predicts risk of first cardiovascular event (CHD, Stroke, PVD, HF) based on the 2008 D'Agostino model.